Remove Consulting Remove Leads Remove Pharmacology
article thumbnail

Angion stock falls after agreeing Elicio Therapeutics merger

pharmaphorum

Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech Elicio Therapeutics.

article thumbnail

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

Across swathes of primary care, pharmacological innovation has stalled; the last new antihypertensive class was introduced in 2007 and new antibiotics have trickled in at a dangerously slow pace. Alzheimer’s is currently the seventh-leading cause of death globally and growing fast.

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

3D Medical Animation: Transforming Healthcare Communication with Precision and Clarity

Infuse Medical

We create animations that appeal to the target audience from depicting pharmacological processes of action to elucidating complicated medical gadgets. Get in touch with us for a consultation or to request a demo. Since this phase forms the basis of the project as whole, it is vital.

Medical 130
article thumbnail

Strategies for Streamlining Small Molecule Formulation Development When Bridging from Candidate Selection to First-in-Human Clinical Testing

Pharmaceutical Technology

Key considerations in the candidate selection stage The first step in a drug development program is choosing the optimum molecule from a range of potential leads that have been optimized within drug discovery. We start by using in-silico modeling of any pre-existing data associated with the lead compounds.

article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

This could lead to significant research waste. This will lead to a higher proportion of these medicines becoming licensed, benefitting a larger number of patients. He leads the pre-clinical and clinical medical cannabis research programmes in Europe and is responsible for the cannabis clinic rollout across the continent.

Medical 98
article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

Prior to joining Fieldfisher, Taly spent four years working as in-house counsel for a leading tech company helping launch products across multiple EU markets. Premier Consulting [Internet]. She obtained a degree in physics from MIT prior to attending University of Pennsylvania Law School. 2018 [cited 2024May]. Lewis BW.

Marketing 103